Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras through iRGD Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer
- 6 December 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (24) , 16828-16842
Abstract
Proteolysis-targeting chimeras (PROTACs) have recently emerged as a promising technology for drug development. However, poor water solubility, limited tissue selectivity, and inadequate tumor penetration pose significant challenges for PROTAC-based therapies in cancer treatment. Herein, we developed an iRGD-PROTAC conjugation strategy utilizing tumor-penetrating cyclic peptide iRGD (CRGDK/RGPD/EC) to deliver PROTACs deep into breast cancer tissues. As a conceptual validation study, iRGD peptides were conjugated with a bromodomain-containing protein 4 (BRD4) PROTAC through a GSH-responsive linker. The resulting iRGD-PROTAC conjugate iPR showed enhanced water solubility, tumor-targeting capability, and penetration within tumor tissues, resulting in increased antibreast cancer efficacy in animal models and patient-derived organoids. This study demonstrates the advantages of combining iRGD and PROTACs in improving drug delivery and highlights the importance of tissue selectivity and penetration ability in PROTAC-based therapeutics.Keywords
Funding Information
- National Key Research and Development Program of China (2022YFC3401500)
- National Natural Science Foundation of China (82003567, 82030105, 82273779)
- Shanghai Rising-Star Program (23QA1403500)
This publication has 37 references indexed in Scilit:
- Tumor penetrating peptides for improved drug deliveryAdvanced Drug Delivery Reviews, 2017
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancerProceedings of the National Academy of Sciences, 2016
- Advancement in integrin facilitated drug deliveryAdvanced Drug Delivery Reviews, 2016
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4Chemistry & Biology, 2015
- Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugatesBiomaterials, 2014
- VEGF targets the tumour cellNature Reviews Cancer, 2013
- Tissue-Penetrating Delivery of Compounds and Nanoparticles into TumorsCancer Cell, 2009
- C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetrationProceedings of the National Academy of Sciences, 2009
- HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of VEGF165Blood, 2009
- A tumor-homing peptide with a targeting specificity related to lymphatic vesselsNature Medicine, 2002